Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
Avion Pharmaceuticals, LLC, signs Captisol® License Agreement with Ligand Pharmaceuticals to develop four new products
Bayer Receives EU Approval for Stivarga for Tumor Treatment
Amgen reports successful late-stage trial of cancer treatment
Bayer and Onyx Say Phase III Trial of Nexavar Breast Cancer Treatment Failed
Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37
Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.
The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.